• Consensus Rating: Hold
  • Consensus Price Target: $26.50
  • Forecasted Upside: 44.26 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.13 (-0.70%)

This chart shows the closing price for MD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MEDNAX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MD

Analyst Price Target is $26.50
▲ +44.26% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for MEDNAX in the last 3 months. The average price target is $26.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 44.26% upside from the last price of $18.37.

This chart shows the closing price for MD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in MEDNAX. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2022Deutsche Bank AktiengesellschaftLower Price Target$24.00 ➝ $16.00Medium
5/2/2022MizuhoLower Price Target$28.00 ➝ $23.00High
2/23/2022Credit Suisse GroupLower Price TargetOutperform$32.00 ➝ $31.00Medium
12/22/2021Credit Suisse GroupLower Price TargetOutperform$33.00 ➝ $32.00Medium
11/4/2021SVB LeerinkLower Price TargetMarket Perform$29.00 ➝ $27.00Low
11/1/2021BMO Capital MarketsLower Price TargetMarket Perform$37.00 ➝ $31.00Medium
10/13/2021Truist FinancialLower Price TargetHold$37.00 ➝ $31.00High
9/27/2021SVB LeerinkInitiated CoverageMarket Perform$29.00Low
8/9/2021Truist FinancialBoost Price TargetHold$32.00 ➝ $37.00Low
8/9/2021MizuhoBoost Price TargetNeutral$30.00 ➝ $32.00High
6/22/2021Stifel NicolausInitiated CoverageHoldMedium
5/10/2021Deutsche Bank AktiengesellschaftBoost Price TargetSell$17.50 ➝ $24.00Medium
5/10/2021MizuhoBoost Price TargetNeutral$20.00 ➝ $30.00Medium
4/14/2021Truist FinancialBoost Price Target$22.00 ➝ $28.00High
2/25/2021Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $25.00Low
2/19/2021CitigroupLower Price Target$24.00 ➝ $22.00Medium
2/19/2021Deutsche Bank AktiengesellschaftBoost Price TargetSell$14.00 ➝ $17.50High
1/5/2021Truist FinancialBoost Price Target$20.00 ➝ $26.00N/A
10/19/2020Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$20.00 ➝ $12.00High
10/6/2020UBS GroupBoost Price TargetSell$11.00 ➝ $14.00High
6/8/2020BMO Capital MarketsBoost Price Target$16.00 ➝ $20.00Medium
6/8/2020Credit Suisse GroupBoost Price TargetOutperform$20.00 ➝ $24.00Low
5/29/2020MizuhoLower Price TargetNeutral$19.00 ➝ $17.00High
5/21/2020SunTrust BanksBoost Price TargetHold$15.00 ➝ $17.00Low
5/11/2020CfraLower Price TargetHold$22.00 ➝ $15.00Low
5/11/2020Credit Suisse GroupLower Price TargetOutperform$22.00 ➝ $20.00High
5/8/2020UBS GroupLower Price TargetSell$18.00 ➝ $11.00Low
5/8/2020Deutsche Bank AktiengesellschaftLower Price Target$24.00 ➝ $15.00Medium
4/21/2020Robert W. BairdLower Price TargetNeutral$21.00 ➝ $16.00High
4/13/2020SunTrust BanksLower Price TargetHold$22.00 ➝ $15.00Medium
3/26/2020Credit Suisse GroupLower Price TargetOutperform$29.00 ➝ $22.00Low
3/3/2020Robert W. BairdLower Price TargetNeutral$24.00 ➝ $21.00High
2/24/2020JPMorgan Chase & Co.Lower Price TargetNeutral$33.00 ➝ $20.00High
2/24/2020Credit Suisse GroupLower Price TargetOutperform$33.00 ➝ $29.00High
2/21/2020CitigroupLower Price TargetNeutral$29.00 ➝ $23.00High
2/21/2020MizuhoLower Price TargetNeutral$25.00 ➝ $22.00High
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$34.00Low
1/3/2020CitigroupDowngradeBuy ➝ Neutral$29.00Medium
12/20/2019JPMorgan Chase & Co.Boost Price TargetNeutral$26.00 ➝ $33.00Low
12/18/2019SunTrust BanksBoost Price TargetHold$27.00 ➝ $30.00Low
12/12/2019Stifel NicolausUpgradeHold ➝ Buy$25.00 ➝ $33.00High
11/1/2019MizuhoSet Price TargetHold$25.00N/A
10/18/2019UBS GroupLower Price TargetSell$19.00 ➝ $18.00High
9/6/2019Bank of AmericaDowngradeNeutral ➝ Underperform$19.00High
8/27/2019Credit Suisse GroupLower Price TargetOutperform$30.00 ➝ $28.00High
8/5/2019BMO Capital MarketsLower Price TargetMarket Perform$32.00 ➝ $25.00Medium
8/2/2019MizuhoLower Price TargetNeutral$26.00 ➝ $24.00High
7/24/2019UBS GroupLower Price TargetSell$20.00Low
5/3/2019CitigroupSet Price TargetBuy$36.00Low
4/11/2019Jefferies Financial GroupLower Price TargetIn-Line ➝ Hold$37.00 ➝ $31.00Medium
2/13/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$44.00 ➝ $42.00Low
2/8/2019MizuhoSet Price TargetHold$36.00Low
1/28/2019MizuhoReiterated RatingHold$38.00Low
1/14/2019CitigroupUpgradeNeutral ➝ Buy$34.88High
1/3/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$34.00Medium
11/16/2018UBS GroupInitiated CoverageSell ➝ Sell$37.00Low
11/6/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$55.00 ➝ $50.00Medium
11/2/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$48.00 ➝ $40.00Low
11/2/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$48.00 ➝ $43.00Low
10/19/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$50.00 ➝ $48.00Medium
9/24/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
9/18/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$60.00 ➝ $50.00Low
8/3/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$47.00 ➝ $55.00High
8/2/2018Stifel NicolausSet Price TargetHold$47.00High
7/12/2018SVB LeerinkInitiated CoverageMarket Perform$50.00Low
5/7/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$57.00Low
5/4/2018CitigroupLower Price TargetNeutral ➝ Neutral$57.00 ➝ $50.00Low
3/27/2018Credit Suisse GroupInitiated CoverageNeutral$57.00Low
3/15/2018Jefferies Financial GroupSet Price TargetHold$58.00Low
2/12/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$46.00 ➝ $58.00Low
2/12/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$46.00 ➝ $55.00Low
2/9/2018MizuhoReiterated RatingNeutral ➝ Neutral$49.00 ➝ $53.00Low
2/9/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$48.00 ➝ $54.00Medium
2/8/2018StephensSet Price TargetBuy$62.00Medium
2/6/2018Jefferies Financial GroupSet Price TargetHold$50.00Medium
1/24/2018MizuhoSet Price TargetHold$49.00Low
1/24/2018Stifel NicolausReiterated RatingHold$56.00Low
12/21/2017SunTrust BanksSet Price TargetHold$55.00Medium
12/13/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$58.00Low
11/3/2017CitigroupLower Price TargetNeutral$52.00 ➝ $47.00N/A
11/3/2017Robert W. BairdBoost Price TargetNeutral$47.00 ➝ $48.00N/A
11/3/2017Jefferies Financial GroupReiterated RatingHold$44.00N/A
11/1/2017KeyCorpSet Price TargetBuy$51.00N/A
10/16/2017BMO Capital MarketsInitiated CoverageMarket Perform$46.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingHold$46.00Medium
9/17/2017KeyCorpUpgradeSector Weight ➝ Overweight$51.00Low
9/3/2017Robert W. BairdReiterated RatingHold$47.00Medium
8/1/2017MizuhoReiterated RatingNeutral$62.00 ➝ $48.00Medium
7/30/2017Jefferies Financial GroupSet Price TargetHold$53.00 ➝ $46.00Medium
7/6/2017Jefferies Financial GroupReiterated RatingHold$50.00 ➝ $53.00Medium
6/22/2017StephensUpgradeEqual Weight ➝ Overweight$55.00 ➝ $68.00High
5/30/2017MizuhoLower Price TargetNeutral ➝ Neutral$64.00 ➝ $58.00Low
5/25/2017Stifel NicolausLower Price TargetHold$65.00 ➝ $58.00Low
(Data available from 5/24/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 17 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 17 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was founded in 1979 and is based in Sunrise, Florida.
Read More

Today's Range

Now: $18.37
Low: $18.21
High: $18.98

50 Day Range

MA: $21.66
Low: $17.53
High: $24.34

52 Week Range

Now: $18.37
Low: $17.17
High: $35.67


534,044 shs

Average Volume

541,268 shs

Market Capitalization

$1.60 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of MEDNAX?

The following Wall Street research analysts have issued stock ratings on MEDNAX in the last twelve months: BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Mizuho, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for MD.

What is the current price target for MEDNAX?

0 Wall Street analysts have set twelve-month price targets for MEDNAX in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 44.3%.
View the latest price targets for MD.

What is the current consensus analyst rating for MEDNAX?

MEDNAX currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MD, but not buy more shares or sell existing shares.
View the latest ratings for MD.

How do I contact MEDNAX's investor relations team?

MEDNAX's physical mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company's listed phone number is (954) 384-0175 and its investor relations email address is [email protected] The official website for MEDNAX is www.mednax.com. Learn More about contacing MEDNAX investor relations.